| Linda Zapchenk, FNP | |
|
20060 Governors Dr, Olympia Fields, IL 60461 | |
| (815) 824-4406 | |
| Not Available |
| Full Name | Linda Zapchenk |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 20060 Governors Dr, Olympia Fields, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841729035 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0000X | Pain Medicine - Pain Medicine | 036115600 (Illinois) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 20915970 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Linda Zapchenk, FNP 8504 W Stuenkel Rd, Frankfort, IL 60423-7752 Ph: () - | Linda Zapchenk, FNP 20060 Governors Dr, Olympia Fields, IL 60461 Ph: (815) 824-4406 |
News Archive
Early Monday morning, the buzz at the International Society of Pharmaceutical Engineers (ISPE) conference in San Diego, California, was that Pfizer Incorporated was planning to sell its massive St. Louis/Chesterfield, Missouri, research site to Monsanto Company (St. Louis).
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.
Researchers in Canada have conducted a study suggesting that novel Cannabis sativa extracts may decrease levels of the host cell receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain viral entry to target tissues.
Carbon dioxide emission reductions required to limit global warming to 2-C are becoming a receding goal based on new figures reported today in the latest Global Carbon Project (GCP) calculations published today in the advanced online edition of Nature Climate Change. "A shift to a 2-C pathway requires an immediate, large, and sustained global mitigation effort" says GCP executive-director and CSIRO co-author of the paper, Dr Pep Canadell.
A new analysis shows that individuals with high levels of genetic variation and elevated exposure to ozone in the environment are at an even higher risk for developing autism than would be expected by adding the two risk factors together.
› Verified 3 days ago